Back
REGENXBIO, Inc. 10K Form
Sell
33
RGNX
REGENXBIO, Inc.
Last Price:
$13.15
Seasonality Move:
-11.95%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-08 | 10Q | RGNX/REGENXBIO, Inc. Quarterly |
| 2023-08-02 | 10Q | RGNX/REGENXBIO, Inc. Quarterly |
| 2023-05-03 | 10Q | RGNX/REGENXBIO, Inc. Quarterly |
| 2022-11-03 | 10Q | RGNX/REGENXBIO, Inc. Quarterly |
| 2022-08-03 | 10Q | RGNX/REGENXBIO, Inc. Quarterly |
| 2022-05-04 | 10Q | RGNX/REGENXBIO, Inc. Quarterly |
Receive RGNX News And Ratings
See the #1 stock for the next 7 days that we like better than RGNX
RGNX Financial Statistics
Sales & Book Value
| Annual Sales: | $83.3M |
|---|---|
| Cash Flow: | $-56.5M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $3.19 |
| Price / Book: | 4.13 |
Profitability
| EPS (TTM): | -3.48960 |
|---|---|
| Net Income (TTM): | $-177.9M |
| Gross Margin: | $33.5M |
| Return on Equity: | -73.5% |
| Return on Assets: | -34.45% |
REGENXBIO, Inc. Earnings Forecast
Key REGENXBIO, Inc. Financial Ratios
-
The Gross Profit Margin over the past 12 years for RGNX is 40.26%.
-
The Selling, General & Administrative Expenses for RGNX have been equal to 91.95% of Gross Profit Margin.
-
The Research & Development expenses have been 230.78% of Revenue.
-
The Net Earning history of RGNX is -272.54% of Total Revenues.
-
Per Share Earnings over the last 12 years have been positive in 6 years.
REGENXBIO, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | RGNX |
| CUSIP: | 75901B |
| Website: | regenxbio.com |
Debt
| Debt-to-Equity Ratio: | 1.66 |
|---|---|
| Current Ratio: | 2.66 |
| Quick Ratio: | 2.4 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
RGNX Technical Analysis vs Fundamental Analysis
Sell
33
REGENXBIO, Inc. (RGNX)
is a Sell
Is REGENXBIO, Inc. a Buy or a Sell?
-
REGENXBIO, Inc. stock is rated a SellThe current REGENXBIO, Inc. [RGNX] share price is $13.16. The Score for RGNX is 33, which is 34% below its historic median score of 50, and infers higher risk than normal.